Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.69 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL649395 | 1.00 | GPR119 (0.69) | GPR119CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL651844 | 0.91 | GPR119 (0.66) | GPR119CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL654092 | 0.91 | GPR119 (0.66) | GPR119CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL14934490 | 0.83 | GPR119 (0.60) | GPR119GRM5GRM1 | |
| SCHEMBL649418 | 0.83 | CHRNB2 (0.53) | GPR119CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3586313 | 0.83 | CHRNB2 (0.54) | GPR119CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3568066 | 0.83 | CHRNB2 (0.54) | GPR119CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3963696 | 0.83 | CHRNB2 (0.54) | GPR119CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL650346 | 0.82 | CHRNB2 (0.48) | GPR119CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL652549 | 0.82 | CHRNB2 (0.48) | GPR119CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119635-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2012-02-21 | — | — | US | disclosed |
| EP-2298775-A1 | Diazabicyclic central nervous system active agents | Abbott Laboratories (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2295437-A1 | Diazabicyclic central nervous system active agents | Abbott Laboratories (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20100016277-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016277-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | GPR119 283/4885CHRNB2 10/4885CHRNB4 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.